The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
McLeod C, Dymock M, Flanagan KL, Plebanski M, Marshall HS, Estcourt MJ, Wadia U, Tjiam MC, Blyth CC, Subbarao K, Mordant FL, Nicholson S, Cain N, Brizuela R, Faust SN, Thornton RB, Ellis Z, Mckenzie A, Marsh JA, Snelling TL, Richmond PC.
McLeod C, et al. Among authors: ellis z.
J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346. Online ahead of print.
J Infect. 2024.
PMID: 39550007
Free article.